Bone Marrow Transplant for Patients With MF
Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.
Fedratinib for Patients With Primary Myelofibrosis
Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.
Ruxolitinib for Patients With Primary Myelofibrosis
MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.
Monitoring Disease Response or Progression in MF
An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.
Recent Updates to NCCN Guidelines on MF Treatment
Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.
Therapeutic Decision-Making for Primary Myelofibrosis
Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.
Diagnosis and Prognosis of Primary Myelofibrosis
A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.
Unmet Needs and Looking Ahead in Essential Thrombocythemia
Unmet needs and current areas that are being studied in in essential thrombocythemia.
The Treatment Spectrum in Essential Thrombocythemia
Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea.
Essential Thrombocythemia: An Overview
Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.
Ongoing Unmet Needs and New Approaches in Myelofibrosis
Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.
A Review of Pacritinib and PACIFICA Data
Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.
The Role of Transplant in Myelofibrosis
Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.
COMFORT Data and Ruxolitinib in Myelofibrosis
A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.
A Look at Fedratinib and the JAKARTA Trials
Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice.
Risk, Prognosis, and Nontransplant Options in Primary Myelofibrosis
Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.
Goals in Treating Low-Risk Primary Myelofibrosis
Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic.
Emerging Therapeutic Options in Polycythemia Vera
What to look forward to in the polycythemia vera space, including new clinical trials.
Real-World Use of Ruxolitinib in Polycythemia Vera
Experts give real-world insight in using ruxolitinib in patients with polycythemia vera.
Polycythemia Vera: An Update on Clinical Trials
Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.
PV Progression and Guideline-Directed Management
Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.
Therapeutic Considerations in Polycythemia Vera
Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.
Diagnosis and Evaluation in Polycythemia Vera
Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.
An Overview of Myeloproliferative Neoplasms
Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.
Individualizing Treatment Approaches in MPN
Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.
Advances in the Management of MPNs
Essential Thrombocythemia: Treatment Optimization
Classifying Patients With Essential Thrombocythemia
Primary Myelofibrosis: Trials of Interest
JAK2 Inhibitor Selection for Primary Myelofibrosis
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512